1. [Ureaplasma urealyticum and Mycoplasma hominis infections in newborns: personal data and review of the literature].
- Author
-
Aujard Y, Maury L, Doit C, Mariani-Kurkdjian P, Baud O, Farnoux C, and Bingen E
- Subjects
- Humans, Infant, Newborn, Macrolides therapeutic use, Risk Factors, Sepsis etiology, Infant, Newborn, Diseases, Mycoplasma Infections drug therapy, Mycoplasma Infections pathology, Mycoplasma hominis pathogenicity, Ureaplasma Infections drug therapy, Ureaplasma Infections pathology, Ureaplasma urealyticum pathogenicity
- Abstract
Ureaplasma urealyticum and Mycoplasma hominis colonized 20-40% of newborns and are more frequent in premature. They are responsible for localized infections such as pleural effusion, pneumopathy, adenopathy, abscess or systemic sepsis. An important hyperleukocytosis is often associated with pulmonary infections. Their responsibility, as pathogen agents, is questionable in some non bacterial meningitis. There is large controversy for their role as cofactor, in chronic lung disease (bronchopulmonary dysplasia) and periventricular leukomalacia, because of a too low number of newborns in prospective trials. Genital mycoplamas are resistant to beta lactamines. Macrolides have a good sensitivity, particularly josamycine, but Mycoplasma hominis is resistant to erythromycin. For systemic sepsis, fluoroquinolones such as ciprofloxacine have less deleterious effects than IV erythromycin.
- Published
- 2005
- Full Text
- View/download PDF